

## February 2, 2024 | Issue 307

#### Editor's note

This note is produced every Friday by <u>KPMG</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list here</u>.

We welcome your feedback. Let us know if KPMG can help. Please reply to this email with any comments or requests.

> Subscribe here



## Healthcare regulatory news

CMS released the <u>2025 Medicare Advantage (MA)/Part D Advance Notice</u>, proposing a net increase in MA plan payments (3.7%), and <u>Part D-related Inflation Reduction Act (IRA) implementation</u> updates (e.g., reducing the out-of-pocket expense cap to \$2,000 and eliminating the Coverage Gap Discount Program)... CMS sent <u>its initial offer price to pharmaceutical manufacturers</u> for the 10 drugs selected for the first year of the Medicare Drug Price Negotiation Program.

CMS announced increased 2024 Medicare ACO participation, including 19 new Medicare Shared Savings Program (MSSP) ACOs receiving \$20M in Advance Investment Payments to care for rural/underserved populations... CMS announced sickle cell disease as the initial focus of the Cell and Gene Therapy (CGT) Access Model for testing outcomes-based agreements of cell and gene therapies among Medicaid beneficiaries.

FDA released its <u>Quality Management System Regulation (QSMR) final</u> <u>rule</u> for medical devices aligning to device quality standards set by the International Organization for Standardization (ISO).

A SAMHSA <u>final rule</u> makes certain pandemic-related flexibilities permanent, including allowing virtual prescribing of opioid treatments.





# Healthcare law and policy news

HCSC plans to <u>acquire Cigna's Medicare business</u> (\$3.7B)... Cardinal Health will <u>acquire Specialty Networks (\$1.2B)</u> to expand its pharmaceutical and specialty segments.

Novo Nordisk to <u>discontinue US sales of Levemir</u>, a long-acting form of Insulin, eight months after the company reduced prices by 65%... Biogen will not seek full FDA approval of its' <u>Alzheimer's treatment</u>, <u>Aduhelm</u> and will discontinue sales after mixed results in early human trials and price concerns.

A *JAMA* study found COVID-19 contributed to substantial <u>healthcare</u> <u>workforce turnover</u>; average quarterly exit rates increased almost 2% from 2018-2021.

A joint AHIP-BCBS survey found No Surprises Act (NSA) protections prevented 10M+ surprise medical bills in the first nine months of 2023... A BDO survey found provider cash reserves remain low despite reported increases in profitability in 2023; less than a third of providers surveyed had more than 60 days cash on hand.

Department of Justice is <u>investigating use of AI embedded in electronic</u> <u>health records</u> to drive physician prescribing decisions.

A new CDC report shows syphilis cases increased 17% in 2022, reaching a 70-year high, with largest increases observed in cases of congenital syphilis (31%), leading some health departments to ration penicillin.





Questions or comments, please send to us-hclspractice@kpmg.com.

#### kpmg.com/socialmedia











Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2024 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. USCS011380-1B

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.